## First-Line Management of Giant Cell Arteritis **Key Point:** High-dose corticosteroids (prednisolone or methylprednisolone) are the gold-standard first-line treatment for GCA. Prompt initiation is critical to prevent irreversible vision loss. ### Pathophysiology GCA is a large-vessel vasculitis affecting the temporal and other large arteries, mediated by: - Granulomatous infiltration of the arterial wall - CD4+ T-cell and macrophage activation - IL-6 and TNF-α-driven inflammation ### Corticosteroid Dosing Regimen | Phase | Dose | Duration | Rationale | |-------|------|----------|----------| | **Induction** | Prednisolone 40–60 mg/day (or IV methylprednisolone 500–1000 mg daily × 3 days) | 2–4 weeks | Rapid suppression of inflammation; prevent vision loss | | **Taper** | Reduce by 10 mg/week to 20 mg/day | 4–8 weeks | Gradual dose reduction while monitoring ESR/CRP | | **Maintenance** | 5–15 mg/day | 12–24 months | Long-term remission maintenance | **High-Yield:** The urgency of corticosteroid initiation: - Visual symptoms (amaurosis fugax, diplopia) signal imminent arteritic anterior ischemic optic neuropathy (AAION) - Permanent blindness can occur within days if untreated - Biopsy confirmation should NOT delay treatment if clinical suspicion is high - ESR and CRP normalize within 1–2 weeks of adequate steroid therapy ### Adjunctive Measures - **Low-dose aspirin (75–100 mg/day):** Reduces thrombotic complications and may lower risk of visual events - **Proton pump inhibitor:** Gastroprotection during prolonged corticosteroid use - **Calcium + vitamin D:** Osteoporosis prevention - **Monitoring:** ESR/CRP at baseline and 2–4 weeks; repeat biopsy if diagnosis uncertain **Clinical Pearl:** Tocilizumab (IL-6 receptor antagonist) is now FDA-approved and increasingly used as a steroid-sparing agent in GCA, especially for steroid-dependent or relapsing disease. However, it is NOT first-line monotherapy — corticosteroids remain the essential initial treatment. **Mnemonic — GCA Management Priorities: "VISION"** - **V**isual symptoms → urgent steroids - **I**nflammatory markers (ESR/CRP) → baseline and follow-up - **S**teroid-sparing agents (tocilizumab) → add if relapse or intolerance - **I**schemic complications → prevent with aspirin - **O**steoporosis prophylaxis → calcium, vitamin D, bisphosphonate - **N**ormalization of markers → guides taper **Warning:** Abrupt steroid withdrawal or too-rapid taper increases relapse risk (up to 50%). Relapses typically occur 6–12 months after diagnosis and require reinduction with higher doses. [cite:Harrison 21e Ch 318]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.